S14 Ep57: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD

OncLive® On Air - Un podcast de OncLive® On Air

Essayez Nextory gratuitement pendant un mois.

Un univers rempli de livres audio, cliquez ici pour essayer

Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.